Coronavirus (COVID-19) Collection
Post-acute symptoms 3-15 months after COVID-19 among unvaccinated and vaccinated individuals with a breakthrough infection
Vaccination represents the most important strategy to prevent infection, severe complications, and death caused by SARS-CoV-2 (Feikin et al., 2022). SARS-CoV-2 vaccination may also reduce the risk of post-acute sequelae of SARS-CoV-2 infection (PASC) (Antonelli et al., 2022; Azzolini et al., 2022; Kuodi et al., 2022), but conflicting results have been presented (Taquet et al., 2022). We aimed to describe self-reported PASC symptoms, including memory and concentration problems, changes in smell and taste, fatigue, and dyspnea, persisting 3-15 months after a positive test in SARS-CoV-2 unvaccinated and vaccinated participants with a breakthrough infection.Immunogenicity and efficacy of COVID-19 vaccines in people living with HIV: a systematic review and meta-analysis
The transmission of SARS-CoV-2 has led to the ongoing global COVID-19 pandemic. By August 19, 2022, more than 590 million have had confirmed COVID-19 and more than 6 million have died worldwide (World Health Organization, 2022). The morbidity and mortality from COVID-19 and its complications and large-scale economic disruption have prompted an unprecedented pace in highly efficacious vaccine development (Berlin et al., 2020; Merad et al., 2022). As of August 19, 2022, a total of 12.4 billion vaccine doses have been administered (World Health Organization, 2022), and the most widely used are messenger RNA (mRNA) vaccines, including BNT162b2 (Pfizer-BioNTech, New York, NY, USA-Mainz, Germany) and mRNA-1273 (Moderna, Cambridge, MA, USA) vaccines and viral vector vaccines, such as Ad26.CoV2.S (Johnson & Johnson, New Brunswick, NJ, USA), ChAdOx (AstraZeneca, Cambridge, UK), Sputnik V (Gamaleya Research Institute of Epidemiology and Microbiology, Moscow, Russia), and the traditional inactivated virus alum-adjuvanted candidate vaccine CoronaVac (Sinovac, Beijing, China) (Piccaluga et al.Epidemiological assessment of SARS-CoV-2 reinfection
COVID-19 began as an outbreak in Wuhan, China, in December 2019 and was declared a pandemic by the World Health Organization (WHO) in March 2020 (WHO, 2020). The disease, caused by SARS-CoV-2, has affected >271,900,000 people worldwide and led to >5,000,000 deaths as of December 19, 2021 (WHO, 2021c). There are currently five SARS-CoV-2 variants that are classified as variants of concern: Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and more recently, Omicron (B.1.1.529) (WHO, 2021b).Rule out appropriately all differentials before attributing severe rhabdomyolysis to SARS-CoV-2 vaccination
We read with interest the article by Kamura et al. about a 57-year-old, previously healthy male patient, who presented with leg pain 2 weeks after the first dose of the Moderna vaccine (Kamura et al., 2022). Four weeks after the vaccination, he was diagnosed with rhabdomyolysis upon the clinical presentation (muscle pain), elevated creatine-kinase (maximal value 74,804 U/l [n, 60-287 U/l]), and the muscle magnetic resonance imaging (MRI) (Kamura et al., 2022). During the following course, the patient additionally developed multiorgan infarctions and, finally, died despite intensive diagnostic and therapeutic approaches (Kamura et al., 2022).Real-world effectiveness of COVID-19 vaccination among children in Italy
In this study, we analyzed the clinical efficacy of mRNA-based COVID-19 vaccines among Italian children aged 5 to 11 years, using data published by the National Institute of Health. Vaccination status was associated with a reduced risk of COVID-19–related hospitalizations and intensive care unit (ICU) admissions, which were 41% (odds ratio, 0.59; 95% confidence interval [CI], 0.46-0.77) and 68% (odds ratio, 0.32; 95% CI, 0.04-2.63), respectively, lower in children who completed the vaccination cycle <120 days than in the unvaccinated matched population.Incidence of SARS-CoV-2 infection among previously infected or vaccinated employees
Prior reports have found lower rates of SARS-CoV-2 infections among those vaccinated against SARS-CoV-2 or with a prior SARS-CoV-2 infection (Dagan et al., 2021; Qureshi et al., 2021). Although an association between vaccination and reduction of SARS-CoV-2 incidence has been well described, it remains unclear how the incidence among individuals with a previous infection compares to vaccinated individuals.Constrictive pericarditis after SARS-CoV-2 vaccination: A case report
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is associated with a wide range of cardiovascular complications such as myocarditis, heart failure, arrhythmias, and venous thromboembolism (Chang et al., 2021). Although SARS-CoV-2 vaccination has been widely adopted to prevent the spread of COVID-19, vaccine-associated cardiovascular complications, such as myocarditis and pericarditis, have been reported (Bozkurt et al., 2021; Pepe et al., 2021).Critical timing and extent of public health interventions to control outbreaks dominated by SARS-CoV-2 variants in Australia: a mathematical modelling study
The coronavirus disease 2019 (COVID-19) pandemic continues to cause a catastrophic health and economic crisis around the world (McKee and Stuckler, 2020; World Health Organization, 2021). To prevent the consequences of the COVID-19 epidemic, 22 vaccine candidates have been approved by the World Health Organization (Craven, 2021). Yet, achieving global herd immunity with these vaccines will take time, given the existing disparity in COVID-19 vaccination across the globe (Forman et al., 2021). Non-pharmaceutical interventions remain the most effective means for COVID-19 control until herd immunity can be achieved.Antibody response to the inactivated SARS-CoV-2 vaccine among healthcare workers, Indonesia
Healthcare workers (HCWs) are at risk for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection due to increased occupational exposure to SARS-CoV-2 (Nguyen et al., 2020). As well as being beneficial for the HCWs themselves, protecting HCWs from SARS-CoV-2 infection is important to prevent disease transmission in healthcare and community settings (Anonymous, 2020). In addition, protecting HCWs from coronavirus disease 2019 (COVID-19) is crucial for the preservation and protection of national healthcare systems (Anonymous, 2020).Hypersensitivity reaction to hyaluronic acid dermal filler after the Pfizer vaccination against SARS-CoV-2
The novel coronovirus (2019-nCoV), named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)has infected approximately 250 million people worldwide killed more than 3.7 million individuals (n.d.). The rapid spreading of the pandemia has stimulated the implementation of numerous measures to combat the spread of the virus, such as closures of geographical areas, lockdowns, restrictions on the circulation of citizens and closure of various types of activities and businesses (Galanakis, 2020).Comparison of an inactivated Covid19 vaccine-induced antibody response with concurrent natural Covid19 infection
The devastating effect of SARS-CoV-2 is still ongoing around the globe (WHO, 2019). Virus-infected patients are either asymptomatic or have the disease, with clinical course ranging from mild to severe (Yang et al. 2020). HCWs have a higher risk of encountering SARS-CoV-2. The higher risk comes from likely contact with patients carrying high viral loads and virus-infected stuff in the hospitals. Infection rates rise up to 14% in symptomatic and 7.1% in asymptomatic HCWs. These rates are higher than the general population reported so far and suggest an occupational risk (Shields et al. 2020).The potential significance of high avidity immunoglobulin G (IgG) for protective immunity towards SARS-CoV-2
The avidity of immunoglobulin G (IgG) is determined by its affinity and denotes the strength of binding to its target epitope. High avidity is reached after affinity/avidity maturation and reflects the best fit between IgG and epitope. Avidity of IgG is low during acute infection and reaches high values several weeks or months later (Hedman et al., 1997; Bauer, 2021). Memory B cells express and utilize high avidity IgG to establish effective anamnestic responses (Eisen, 2014).
